Efficacy and Safety of Seltorexant as Adjunctive Therapy in Major Depressive Disorder: A Phase 2b, Randomized, Placebo-Controlled, Adaptive Dose-Finding Study
Adam Savitz(Janssen (United States)), Wayne C. Drevets(Johnson & Johnson (United States)), Yun Zhang(Janssen (United States)), Haiyan Xu(Unknown), Mila Etropolski(Consumer Healthcare Products Association), Michael E. Thase(Veterans Health Administration), Ewa Wajs(Janssen (Belgium))
Cited by 63
Related Papers
The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression
|Biological Psychiatry|2003|3.9k
Subgenual prefrontal cortex abnormalities in mood disorders
|Nature|1997|2.7k
Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression
|Brain Structure and Function|2008|2.2k
Neurocircuitry of Mood Disorders
|Neuropsychopharmacology|2009|1.6k
A Comparison of Nefazodone, the Cognitive Behavioral-Analysis System of Psychotherapy, and Their Combination for the Treatment of Chronic Depression
|New England Journal of Medicine|2000|1.3k